Cellectis in offering of US$175m ADS following asset swap – European Biotechnology
European Biotechnology |
Cellectis in offering of US$175m ADS following asset swap
European Biotechnology Cellectis' CAR T platform use engineered T-cells from a healthy donor for use in multiple patients. This is distinct from autologous approaches that use a patient's own T-cells to target tumor cells. Since manufacturing of autologous CAR T cell … |
